London, 11 May 2015: Technavio, the independent tech-focused global research firm, has published a report on the global neurodegenerative diseases market 2015-2019, which is expected to grow at a CAGR of 4.77 % during the forecast period of 2014-2019.
“Epilepsy represents a high level of unmet medical need in terms of the absence of any disease-modifying treatment. Currently, drugs used to treat the disorder are intended to treat seizures and fail to check the progression of the disease. These drugs cannot reverse the neuronal damage incurred by the patient.”
“Drug delivery systems like transdermal patches, ER formulations and orally disintegrating tablets have increased drug efficacy because of the growing patient compliance and bioavailability of a drug,” says Faisal Ghaus, Vice President of Technavio.
“Reduction in side effects increases drug acceptance among patients and drives revenue growth. The dry syrup formulation of Aricept allows the adjustment of individual dose along with reducing the bulk of the drug, making it easier to swallow.”
Key Market Drivers
- Unmet Medical Needs
- Increase in Patient Population
- Promising Drug Pipeline
- Special Provision for Rare Diseases
Key Market Trends
- Reformulation of Marketed Drugs
- Emerging Treatment Options
- Increase in Public Awareness
Key Market Vendors
- Biogen Idec Inc.
- Merck Serono SA
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- UCB SA
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
